Sign up to all DiabetesontheNet journals
Journals
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Diabetes Digest
Issue:
Early View
Health inequality and diabetes: Practical consequences for the clinician
The COVID-19 pandemic has sharply highlighted the health inequality within our society. We have seen a disease that targets particular groups because of social circumstances and then leads to a more severe disease course in those same groups. It feels unfair because it is unfair.
This information is not new. For many years we have studied the causes and consequences of health inequality but have had mixed results in addressing the problem. We assume that the differences happen before the individual reaches specialist care and that, at this point, the care delivered is the same for all. As diabetes specialists, we may feel that working to reduce health inequality involves lobbying for improved social care or access to primary health resources. However, this interesting paper by Walker and colleagues suggests that this may not be the full story.
The authors examined disparities in a specific area of diabetes care: the use of advanced technology in the management of type 1 diabetes. Although the paper describes two populations within the USA, a country with much sharper contrasts in healthcare delivery than the UK, the lessons can nonetheless be used to improve care within this country.
Two groups of people with type 1 diabetes were asked to join the study: one group in Florida and the other in California. People were invited if they had been admitted to hospital with diabetic ketoacidosis or if they had an HbA1c >75 mmol/mol (9.0%) and had not attended two or more of their specialist appointments within the previous year. Participants attended focus groups and were asked a series of targeted questions to explore the barriers to using technology to improve diabetes care. The obvious financial barriers, such as lack of health insurance, were identified. Some less obvious factors, however, were revealed, such as the perceived negative attitude of the diabetes team to use of technology. California participants described similar experiences to those from Florida, noting that “endocrinologists are more like the judges…and the visits I’m on trial”. Certainly in the UK, lack of attendance at previous appointments would be a strong factor against the use of pump therapy. These data would suggest a more complicated picture.
This paper once more shows that those at the highest need are the least likely to receive diabetes healthcare. This is true all of the way through the health system. It may be harder to provide care for some social groups, and so we may have to think of different ways to engage and deliver care. The first step is to recognise that this is the case and then think about innovative ways of delivering care. It would be interesting and helpful to see units presenting audit data of technology use across socioeconomic groups within their service.
Click here to read the Digest.
My patient is on a statin. Why are they not also on an SGLT2 inhibitor?
Healthcare costs of type 2 diabetes-related complications
Early glycaemic control and subsequent glycaemic stability improve cardiovascular outcomes in type 2 diabetes
Simulated cost-effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors
Cardiorenal effects of dapagliflozin according to renal function at initiation
Ready-to-use glucagon as a treatment for hypoglycaemia
Mini-dose glucagon to treat hypoglycaemia during Ramadan fasting
My patient is on a statin. Why are they not also on an SGLT2 inhibitor?
Vinod Patel highlights the costs associated with diabetes complications and the savings that can be made by preventing them.
10 Jun 2022
Healthcare costs of type 2 diabetes-related complications
Finnish study estimates mean costs of €11,798 in the first year after an event.
10 Jun 2022
Early glycaemic control and subsequent glycaemic stability improve cardiovascular outcomes in type 2 diabetes
Poor control in the first year of diagnosis and greater HbA1c variability thereafter confer the greatest risk.
10 Jun 2022
Simulated cost-effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors
Cardiovascular benefits make SGLT2 inhibitors highly cost-effective in people with type 2 diabetes regardless of CVD history.
10 Jun 2022